Close
Help
Need Help?



Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine Joins COPE

Posted Tue, Jul, 24,2012

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine has formally joined the Committee on Publishing Ethics.COPE provides guidelines that are applied in situations such as where plagiarism allegations are made against a paper.  By becoming a COPE member there can be no doubt amongst authors of questionable papers that journals will apply commonly accepted industry-stand...

Continue Reading →

Drug Target Insights Added to Gale Academic OneFile

Posted Tue, Jul, 24,2012

Libertas is pleased to announce that Drug Target Insights has now been added to Gale's Academic OneFile database.GALE operates more than 600 databases, including the popular InfoTrac and General Reference series. The Michigan based company is popular with authors working in the USA, so inclusion of Drug Target Insights in GALE's Academic OneFile will increase article visibility in North Am...

Continue Reading →

Magnetic Resonance Insights Email Alerts

Posted Tue, Jul, 24,2012

A key component of Libertas' high quality service to Magnetic Resonance Insights authors and readers is the free email alerts service, which keeps recipients updated on Magnetic Resonance Insights newly published articles and journal news.Email alerts recipients receive short, plain text notifications whenever a new article is published.  Notifications are also provided for forthcoming pa...

Continue Reading →

Posted in: Libertas Services

Join the Lymphoma and Chronic Lymphocytic Leukemias Peer Reviewer Community

Posted Tue, Jul, 24,2012

Libertas encourages readers to register to join the Lymphoma and Chronic Lymphocytic Leukemias peer review group.  Being a volunteer peer reviewer is a great way to support Lymphoma and Chronic Lymphocytic Leukemias and assist your colleagues who have submitted manuscripts to the journal.The peer review process has been designed to make this vital task as quick and well-organized as possible ...

Continue Reading →

Pubmed and Open Access Visibility in Drug Target Insights

Posted Tue, Jul, 24,2012

Articles published in open access journals like Drug Target Insights are more visible and likely to receive more citations than articles published in restricted access journals.During June, Pubmed Central statistics showed that Libertas Academica has 1,358 papers available for anyone to download for free. These papers received 31,330 views, including 8,020 downloads. The most popular paper was vie...

Continue Reading →

New Evolutionary Bioinformatics Call for Papers

Posted Tue, Jul, 24,2012

Impact factor has been updated since this news item was released.  To see the current impact factor visit the Evolutionary Bioinformatics homepage. The Editor in Chief, Dr Dennis Wall, is pleased to announce a new call for papers for Evolutionary Bioinformatics. Submissions are being accepted now.All authors who submit their manuscripts to Libertas will benefit from:Convenient 3-step online m...

Continue Reading →

Posted in: Calls for Papers

Our Service Promise

  • Prompt Processing (3 Weeks to Editorial Decision)
  • Fair, Independent Peer Review
  • High Visibility & Extensive Indexing
What Your Colleagues Say About Libertas Academica
I would like to express my gratitude to all the staff of LA's journals.  I published twice and I will certainly continue with LA's journals in the future.  Thank you for providing a sustainable publishing environment for us.
Professor Amira Helmy (Theodor Bilhars Research Institute, Egypt)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results